Amgen (AMGN) Other Non-Current Liabilities (2009 - 2026)

Amgen has reported Other Non-Current Liabilities for 18 years, with the latest figure at $2.8 billion in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 13.26% year-over-year to $2.8 billion in Q2 2026; TTM through Jun 2026 was $2.8 billion, a 13.26% increase from a year earlier, with the FY2025 full-year figure at $2.7 billion, up 14.52% from the prior year.
• Other Non-Current Liabilities was $2.8 billion for Q2 2026 at Amgen, up from $2.8 billion in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $6.7 billion in Q1 2022, with the low at $96.0 million in Q1 2024.
• Average Other Non-Current Liabilities over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities plunged 98.27% in 2023, then surged 2419.79% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $270.0 million in 2022, then jumped by 1633.33% to $4.7 billion in 2023, then slumped by 49.81% to $2.3 billion in 2024, then gained by 14.52% to $2.7 billion in 2025, then climbed by 5.72% to $2.8 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.8 billion (Q2 2026), $2.8 billion (Q1 2026), and $2.7 billion (Q4 2025), per Business Quant data.